Teriflunomide side effects: what 44,957 FDA adverse event reports show
Drug class
Pyrimidine Synthesis Inhibitor
Who reports
44,957 reports · 43% serious · 726 with death outcome · 80% female
Used for
Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Teriflunomide is pyrimidine .
What it is
Teriflunomide is an oral de novo pyrimidine synthesis inhibitor of the DHO-DH enzyme, with the chemical name (Z)-2-Cyano-3-hydroxy-but-2-enoic acid-(4-trifluoromethylphenyl)-amide.
Boxed warning
HEPATOTOXICITY and EMBRYOFETAL TOXICITY Hepatotoxicity Clinically significant and potentially life-threatening liver injury, including acute liver failure requiring transplant, has been reported in patients treated with teriflunomide in the postmarketing setting [see Warnings and Precautions ( 5.1 )] .
Causality screen of the 40 strongest signals
What the badges mean
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,076 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Multiple sclerosis relapse | 5,230 | 38.1 37.1–39.2ROR 43.0 · calibrated p 3e-5 ✓ | 35.3 EB05 34.5 · IC025 +5.1 3/3 methods agree | Labeled (related wording) related wording | serious PRR 62.4 | NCT00751881: 1/233 (0.4%) on Teriflunomide; 2/385 (0.5%) control (serious AE) |
| Band sensation | 96 | 37.8 30.7–46.6ROR 37.9 · calibrated p 8e-5 ✓ | 34.8 EB05 29.4 · IC025 +4.6 3/3 methods agree | Not in label — unassessed | serious n=69 · 72% consumer | not reported in cached trials |
| Relapsing multiple sclerosis | 17 | 27.4 16.8–44.7ROR 27.4 · calibrated p 8e-4 ✓ | 25.2 EB05 16.6 · IC025 +3.1 3/3 methods agree | Likely indication confounding term in indications; also in warnings | serious n=16 | not reported in cached trials |
| Nuclear magnetic resonance imaging abnormal | 176 | 25.7 22.1–29.9ROR 25.8 · calibrated p 6e-4 ✓ | 24.4 EB05 21.5 · IC025 +4.3 3/3 methods agree | Reporting / coding artifact | serious n=147 · 81% consumer | not reported in cached trials |
| Progressive multiple sclerosis | 60 | 25.1 19.4–32.6ROR 25.2 · calibrated p 8e-4 ✓ | 23.7 EB05 19.1 · IC025 +3.9 3/3 methods agree | Likely indication confounding term in indications; also in warnings | serious n=56 | not reported in cached trials |
| Jc virus test positive | 41 | 23.5 17.2–32.2ROR 23.5 · calibrated p 0.001 ✓ | 22.2 EB05 17.1 · IC025 +3.6 3/3 methods agree | Lab value / disease marker | serious n=32 · 78% consumer | not reported in cached trials |
| Secondary progressive multiple sclerosis | 91 | 23.5 19.0–29.0ROR 23.5 · calibrated p 0.001 ✓ | 22.3 EB05 18.7 · IC025 +4.0 3/3 methods agree | Likely indication confounding term in indications; also in warnings | serious n=86 | not reported in cached trials |
| Decreased interest | 282 | 23.4 20.7–26.3ROR 23.5 · calibrated p 1e-3 ✓ | 22.2 EB05 20.1 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=109 · 75% consumer | not reported in cached trials |
| Eosinophilic colitis | 17 | 23.1 14.2–37.6ROR 23.1 · calibrated p 0.002 ✓ | 21.5 EB05 14.1 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=17 | not reported in cached trials |
| Multiple sclerosis | 2,221 | 22.6 21.6–23.5ROR 23.7 · calibrated p 9e-4 ✓ | 21.5 EB05 20.8 · IC025 +4.4 3/3 methods agree | Likely indication confounding term in indications; also in warnings | serious PRR 40.4 | NCT00751881: 1/233 (0.4%) on Teriflunomide; 2/385 (0.5%) control (serious AE) |
| Multiple sclerosis pseudo relapse | 15 | 22.2 13.2–37.2ROR 22.2 · calibrated p 0.002 ✓ | 20.6 EB05 13.0 · IC025 +2.8 3/3 methods agree | Labeled (related wording) related wording | serious n=14 | not reported in cached trials |
| Relapsing-remitting multiple sclerosis | 39 | 22.0 16.0–30.4ROR 22.1 · calibrated p 0.002 ✓ | 20.9 EB05 15.9 · IC025 +3.5 3/3 methods agree | Likely indication confounding term in indications; also in warnings | serious n=37 | not reported in cached trials |
| Bladder disorder | 421 | 20.6 18.7–22.7ROR 20.8 · calibrated p 0.002 ✓ | 19.7 EB05 18.2 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=201 | NCT04338061: 1/581 (0.2%) on Teriflunomide (serious AE) |
| Expanded disability status scale score increased | 52 | 20.3 15.4–26.8ROR 20.3 · calibrated p 0.002 ✓ | 19.3 EB05 15.3 · IC025 +3.6 3/3 methods agree | Lab value / disease marker | serious n=52 | not reported in cached trials |
| Walking aid user | 274 | 20.1 17.8–22.7ROR 20.2 · calibrated p 0.002 ✓ | 19.3 EB05 17.4 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=235 · 73% consumer | not reported in cached trials |
| Jc polyomavirus test positive | 48 | 19.8 14.8–26.4ROR 19.8 · calibrated p 0.003 ✓ | 18.9 EB05 14.8 · IC025 +3.5 3/3 methods agree | Lab value / disease marker | serious n=36 | not reported in cached trials |
| Primary progressive multiple sclerosis | 18 | 18.0 11.2–28.8ROR 18.0 · calibrated p 0.005 ✓ | 16.8 EB05 10.9 · IC025 +2.8 3/3 methods agree | Likely indication confounding term in indications; also in warnings | serious n=17 | not reported in cached trials |
| Throat clearing | 136 | 17.7 14.9–21.0ROR 17.7 · calibrated p 0.004 ✓ | 17.0 EB05 14.7 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=79 | not reported in cached trials |
| Trigeminal neuralgia | 139 | 16.7 14.1–19.7ROR 16.7 · calibrated p 0.005 ✓ | 16.1 EB05 13.9 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=97 · 73% consumer | not reported in cached trials |
| Wheelchair user | 145 | 15.6 13.2–18.4ROR 15.7 · calibrated p 0.006 ✓ | 15.1 EB05 13.1 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=134 · 79% consumer | not reported in cached trials |
| Muscle spasticity | 398 | 15.4 14.0–17.1ROR 15.6 · calibrated p 0.006 ✓ | 15.0 EB05 13.8 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious PRR 14.0 | not reported in cached trials |
| Alopecia (hair loss) | 6,076 | 14.8 14.5–15.2ROR 17.0 · calibrated p 0.004 ✓ | 14.4 EB05 14.1 · IC025 +3.8 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 13.7 · 71% consumer | NCT00751881: 5/233 (2.1%) on Teriflunomide; 16/385 (4.2%) control |
| Magnetic resonance imaging abnormal | 36 | 14.7 10.5–20.5ROR 14.7 · calibrated p 0.009 ✓ | 14.0 EB05 10.4 · IC025 +3.0 3/3 methods agree | Reporting / coding artifact | serious n=25 | not reported in cached trials |
| Peroneal nerve palsy | 172 | 14.5 12.5–16.9ROR 14.6 · calibrated p 0.008 ✓ | 14.1 EB05 12.4 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=115 · 77% consumer | not reported in cached trials |
| Meningoencephalitis herpetic | 13 | 13.7 7.9–23.8ROR 13.7 · calibrated p 0.016 ✓ | 12.0 EB05 6.7 · IC025 +2.3 3/3 methods agree | Not in label — unassessed | serious n=13 | not reported in cached trials |
| Optic neuritis | 258 | 13.6 12.0–15.3ROR 13.6 · calibrated p 0.011 ✓ | 13.2 EB05 11.9 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious PRR 19.7 | not reported in cached trials |
| Central nervous system lesion | 371 | 12.8 11.6–14.2ROR 12.9 · calibrated p 0.013 ✓ | 12.5 EB05 11.4 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious PRR 17.7 · 71% consumer | not reported in cached trials |
| Bladder catheterisation | 25 | 12.4 8.3–18.4ROR 12.4 · calibrated p 0.019 ✓ | 11.4 EB05 7.8 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious n=21 · 100% consumer | not reported in cached trials |
| Dysgraphia | 158 | 11.4 9.7–13.3ROR 11.4 · calibrated p 0.021 ✓ | 11.0 EB05 9.6 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=139 · 84% consumer | not reported in cached trials |
| Vitamin d increased | 14 | 10.8 6.4–18.4ROR 10.8 · calibrated p 0.035 ✓ | 9.1 EB05 5.4 · IC025 +2.1 3/3 methods agree | Lab value / disease marker | serious n=11 | not reported in cached trials |
| Hypoaesthesia (numbness) | 3,172 | 10.1 9.7–10.4ROR 10.8 · calibrated p 0.025 ✓ | 9.9 EB05 9.6 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious PRR 11.6 | NCT00751881: 1/371 (0.3%) on Teriflunomide (serious AE) |
| Heat exhaustion | 16 | 9.9 6.0–16.2ROR 9.9 · calibrated p 0.044 ✓ | 8.4 EB05 5.2 · IC025 +2.1 3/3 methods agree | Not in label — unassessed | serious n=12 | not reported in cached trials |
| Balance disorder | 1,786 | 9.8 9.4–10.3ROR 10.2 · calibrated p 0.030 ✓ | 9.6 EB05 9.2 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious PRR 12.4 | not reported in cached trials |
| Temperature intolerance | 192 | 8.9 7.7–10.3ROR 9.0 · calibrated p 0.048 ✓ | 8.7 EB05 7.7 · IC025 +2.9 3/3 methods agree | Not in label — unassessed | serious n=128 · 78% consumer | not reported in cached trials |
| Jc virus infection | 30 | 8.9 6.2–12.8ROR 8.9 · calibrated p 0.054 | 8.1 EB05 5.8 · IC025 +2.3 3/3 methods agree | Labeled (related wording) related wording | serious n=29 | not reported in cached trials |
| Bladder dysfunction | 19 | 8.8 5.6–13.8ROR 8.8 · calibrated p 0.062 | 7.5 EB05 5.0 · IC025 +2.1 3/3 methods agree | Not in label — unassessed | serious n=13 | not reported in cached trials |
| Fine motor skill dysfunction | 53 | 8.7 6.6–11.4ROR 8.7 · calibrated p 0.055 | 8.2 EB05 6.4 · IC025 +2.5 3/3 methods agree | Not in label — unassessed | serious n=36 | not reported in cached trials |
| Paraesthesia (tingling/numbness) | 2,814 | 8.5 8.2–8.8ROR 9.0 · calibrated p 0.047 ✓ | 8.3 EB05 8.1 · IC025 +3.0 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 9.9 | NCT00751881: 4/233 (1.7%) on Teriflunomide; 23/385 (6.0%) control |
| Functional gastrointestinal disorder | 61 | 8.3 6.5–10.7ROR 8.3 · calibrated p 0.062 | 7.9 EB05 6.3 · IC025 +2.5 3/3 methods agree | Not in label — unassessed | serious n=32 | not reported in cached trials |
| Sensory disturbance | 281 | 8.3 7.3–9.3ROR 8.3 · calibrated p 0.060 | 8.1 EB05 7.3 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious PRR 8.6 | not reported in cached trials |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Teriflunomide as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (6 of 40 signal terms matched).
- NCT00751881 — An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis (N=1169, PHASE3; 227 AE terms posted; arms: Placebo; Teriflunomide 7 mg; Teriflunomide 14 mg; Placebo / 14 mg)
- NCT04338061 — Study of Evobrutinib in Participants With RMS (evolutionRMS 2) (N=1166, PHASE3; 106 AE terms posted; arms: Teriflunomide; Evobrutinib)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Alopecia (hair loss) | 6,076 | 14.8 14.5–15.2ROR 17.0 · calibrated p 0.004 ✓ | 14.4 EB05 14.1 · IC025 +3.8 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 13.7 · 71% consumer | NCT00751881: 5/233 (2.1%) on Teriflunomide; 16/385 (4.2%) control |
| Multiple sclerosis relapse | 5,230 | 38.1 37.1–39.2ROR 43.0 · calibrated p 3e-5 ✓ | 35.3 EB05 34.5 · IC025 +5.1 3/3 methods agree | Labeled (related wording) related wording | serious PRR 62.4 | NCT00751881: 1/233 (0.4%) on Teriflunomide; 2/385 (0.5%) control (serious AE) |
| Fatigue (tiredness) | 4,765 | 2.9 2.8–3.0ROR 3.1 · calibrated p 0.596 | 2.9 EB05 2.8 · IC025 +1.5 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 3.6 | NCT00751881: 6/233 (2.6%) on Teriflunomide; 40/385 (10.4%) control |
| Diarrhoea (diarrhea) | 4,759 | 3.5 3.4–3.6ROR 3.8 · calibrated p 0.425 | 3.5 EB05 3.4 · IC025 +1.7 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 3.4 | NCT00751881: 1/371 (0.3%) on Teriflunomide (serious AE) |
| Fall | 3,342 | 4.7 4.6–4.9ROR 5.0 · calibrated p 0.232 | 4.7 EB05 4.6 · IC025 +2.2 3/3 methods agree | Not in label — unassessed | serious PRR 4.3 · 71% consumer | NCT00751881: 2/409 (0.5%) on Teriflunomide; 2/385 (0.5%) control (serious AE) |
| Hypoaesthesia (numbness) | 3,172 | 10.1 9.7–10.4ROR 10.8 · calibrated p 0.025 ✓ | 9.9 EB05 9.6 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious PRR 11.6 | NCT00751881: 1/371 (0.3%) on Teriflunomide (serious AE) |
| Headache | 3,003 | 2.2 2.2–2.3ROR 2.3 · calibrated p 0.888 | 2.2 EB05 2.2 · IC025 +1.1 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 2.7 | NCT00751881: 1/371 (0.3%) on Teriflunomide; 3/385 (0.8%) control (serious AE) |
| Drug ineffective (drug did not work) | 2,819 | 1.0 1.0–1.0ROR 1.0 · calibrated p 0.306 | 1.0 EB05 1.0 · IC025 -0.1 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | serious PRR 1.4 | not reported in cached trials |
| Paraesthesia (tingling/numbness) | 2,814 | 8.5 8.2–8.8ROR 9.0 · calibrated p 0.047 ✓ | 8.3 EB05 8.1 · IC025 +3.0 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 9.9 | NCT00751881: 4/233 (1.7%) on Teriflunomide; 23/385 (6.0%) control |
| Nausea | 2,746 | 1.6 1.6–1.7ROR 1.7 · calibrated p 0.748 | 1.6 EB05 1.6 · IC025 +0.6 | Labeled adverse reaction exact term | serious PRR 2.1 · 71% consumer | NCT00751881: 8/233 (3.4%) on Teriflunomide; 27/385 (7.0%) control |
| Gait disturbance | 2,489 | 6.1 5.9–6.4ROR 6.4 · calibrated p 0.126 | 6.0 EB05 5.8 · IC025 +2.5 3/3 methods agree | Not in label — unassessed | serious PRR 8.1 · 73% consumer | not reported in cached trials |
| Pain | 2,236 | 1.7 1.6–1.8ROR 1.7 · calibrated p 0.790 | 1.7 EB05 1.6 · IC025 +0.7 | Labeled adverse reaction exact term | serious PRR 2.2 | NCT00751881: 1/371 (0.3%) on Teriflunomide (serious AE) |
| Multiple sclerosis | 2,221 | 22.6 21.6–23.5ROR 23.7 · calibrated p 9e-4 ✓ | 21.5 EB05 20.8 · IC025 +4.4 3/3 methods agree | Likely indication confounding term in indications; also in warnings | serious PRR 40.4 | NCT00751881: 1/233 (0.4%) on Teriflunomide; 2/385 (0.5%) control (serious AE) |
| Condition aggravated | 2,016 | 3.1 3.0–3.3ROR 3.2 · calibrated p 0.557 | 3.1 EB05 3.0 · IC025 +1.6 3/3 methods agree | Reporting / coding artifact | serious PRR 3.7 | not reported in cached trials |
| Depression | 1,790 | 3.7 3.5–3.8ROR 3.8 · calibrated p 0.420 | 3.7 EB05 3.5 · IC025 +1.8 3/3 methods agree | Not in label — unassessed | serious PRR 3.3 · 71% consumer | NCT00751881: 1/267 (0.4%) on Teriflunomide; 1/385 (0.3%) control (serious AE) |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Band sensation — n=96, PRR 37.8
- Decreased interest — n=282, PRR 23.4
- Bladder disorder — n=421, PRR 20.6 (also seen in trial arm)
- Walking aid user — n=274, PRR 20.1
- Throat clearing — n=136, PRR 17.7
- Trigeminal neuralgia — n=139, PRR 16.7
- Wheelchair user — n=145, PRR 15.6
- Muscle spasticity — n=398, PRR 15.4
- Peroneal nerve palsy — n=172, PRR 14.5
- Optic neuritis — n=258, PRR 13.6
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Teriflunomide?
In FDA FAERS, the most frequently co-reported reaction terms for Teriflunomide are alopecia, multiple sclerosis relapse, fatigue, diarrhoea, fall, hypoaesthesia. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Teriflunomide have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: HEPATOTOXICITY and EMBRYOFETAL TOXICITY Hepatotoxicity Clinically significant and potentially life-threatening liver injury, including acute liver failure requiring transplant, has been reported in patients treated with teriflunomide in the postmarketing setting [see Warnings and Precautions ( 5.1 )] .
Do FAERS signals prove that Teriflunomide causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 2d2724f6-8812-4a26-b2ec-936b71f868e1, effective 20260506; matched on
openfda.generic_name.exact:"TERIFLUNOMIDE") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,116 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
TERIFLUNOMIDE, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.